{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T19:08:12Z","timestamp":1648753692469},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.jash.2011.12.002","type":"journal-article","created":{"date-parts":[[2012,2,3]],"date-time":"2012-02-03T08:48:14Z","timestamp":1328258894000},"page":"219-227","source":"Crossref","is-referenced-by-count":4,"title":["Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with Stage 2 hypertension"],"prefix":"10.1016","volume":"6","author":[{"given":"Keith C.","family":"Ferdinand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Weitzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Das","family":"Purkayastha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanaka","family":"Sridharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar A.","family":"Jaimes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2011.12.002_bib1","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2010.650","article-title":"US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008","volume":"303","author":"Egan","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2011.12.002_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/HPC.0b013e318053da59","article-title":"The management of hypertension in African Americans","volume":"6","author":"Ferdinand","year":"2007","journal-title":"Crit Pathw Cardiol"},{"issue":"Suppl","key":"10.1016\/j.jash.2011.12.002_bib3","first-page":"94","article-title":"Prevalence of hypertension and controlled hypertension\u2013United States, 2005-2008","volume":"60","author":"Keenan","year":"2011","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.jash.2011.12.002_bib4","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/HJH.0b013e328302ca38","article-title":"The metabolic syndrome in hypertension: European society of hypertension position statement","volume":"26","author":"Redon","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2011.12.002_bib5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/HYPERTENSIONAHA.108.113357","article-title":"Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004","volume":"52","author":"Cutler","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2011.12.002_bib6","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.295.13.1549","article-title":"Prevalence of overweight and obesity in the United States, 1999-2004","volume":"295","author":"Ogden","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2011.12.002_bib7","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2011.12.002_bib8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jash.2011.01.006","article-title":"Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension","volume":"5","author":"Ferdinand","year":"2011","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.jash.2011.12.002_bib9","first-page":"210A","article-title":"Recommendations for human blood pressure determination by sphygmomanometers: report of a special task force appointed by the Steering Committee, American Heart Association","volume":"11","author":"Frohlich","year":"1988","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2011.12.002_bib10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/HYPERTENSIONAHA.110.152892","article-title":"Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement","volume":"56","author":"Flack","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2011.12.002_bib11","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2011.12.002_bib12","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2011.12.002_bib13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/01.HYP.0000101687.89160.19","article-title":"Determinants of salt sensitivity in black and white normotensive and hypertensive women","volume":"42","author":"Wright","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2011.12.002_bib14","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1185\/03007990902785845","article-title":"Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension","volume":"25","author":"Littlejohn","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jash.2011.12.002_bib15","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1524-6175.2007.06614.x","article-title":"Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy","volume":"9","author":"Drummond","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jash.2011.12.002_bib16","unstructured":"Braun-Dullaeus RC, Zhang J, Hristoskova S, H\u00e4ring DA, Liao W. First-line therapy with aliskiren\/amlodipine combination provides robust blood pressure reductions in patients with moderate to severe hypertension. Presented at the 25th Annual Scientific Meeting and Exposition of the American Society of Hypertension. May 1\u20134, 2010, New York."},{"key":"10.1016\/j.jash.2011.12.002_bib17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(10)62003-X","article-title":"Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial","volume":"377","author":"Brown","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2011.12.002_bib18","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/HJH.0b013e32832be593","article-title":"Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial","volume":"27","author":"Schmieder","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2011.12.002_bib19","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1751-7176.2011.00483.x","article-title":"Comparative efficacy and safety of combination aliskiren\/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension","volume":"13","author":"Black","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jash.2011.12.002_bib20","first-page":"489","article-title":"Comparative efficacy and safety of combination aliskiren\/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome","volume":"5","author":"Weinberger","year":"2011","journal-title":"J\u00a0Am Soc Hypertens"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171111003159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171111003159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T10:57:55Z","timestamp":1543229875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171111003159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1933171111003159"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2011.12.002","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}